LETROZOL Accord 2,5 mg Filmtabletten 1 0 1 Carefarm

Description

Excipients

Lactose monohydrate – 50 mg, sodium carboxymethyl starch – 2.5 mg, colloidal silicon dioxide – 0.5 mg, microcrystalline cellulose – 28 mg, crospovidone – 4 mg, pregelatinised maize starch – 11.5 mg, magnesium stearate – 1 mg.

Composition of the coating

opadray Y 1-7000 (hypromellose, titanium dioxide, macrogol (polyethylene glycol)) – 3.73 mg, yellow iron oxide – 0.27 mg.

Indications

• Early stages of invasive breast cancer whose cells have hormone receptors, in postmenopausal women, as adjuvant therapy.
• Early stage invasive breast cancer in postmenopausal women after completion of standard adjuvant therapy with tamoxifen for 5 years as prolonged adjuvant therapy.
• Disseminated hormone-dependent breast cancer in postmenopausal women (first-line therapy).
• Disseminated breast cancer with disease recurrence or progression in postmenopausal women (natural or artificially induced) who have received prior anti-estrogen therapy.
• Hormone-dependent HER-2 negative breast cancer in postmenopausal women as neoadjuvant therapy when chemotherapy is contraindicated and emergency surgery is not required.